- Nishio M, Kim DW, Wu YL, et al. Crizotinib versus chemotherapy in Asian patients with ALK-positive advanced non-small cell lung cancer. Cancer Res Treat. 2018;50(3):691–700.
- Pan Y, Zhang Y, Li Y, et al. ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features. Lung Cancer. 2014;84(2):121–126. doi: 10.1016/j.lungcan.2014.02.007.
- Travis WD, Brambilla E, Nicholson AG, et al; WHO panel. The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol. 2015;10(9):1243–1260. doi: 10.1097/JTO.0000000000000630.
- Kadota K, Yeh YC, Sima CS, et al. The cribriform pattern identifies a subset of acinar predominant tumors with poor prognosis in patients with stage I lung adenocarcinoma: a conceptual proposal to classify cribriform predominant tumors as a distinct histologic subtype. Mod Pathol. 2014;27(5):690–700. doi: 10.1038/modpathol.2013.188.
- Chiarle R, Voena C, Ambrogio C, Piva R, Inghirami G. The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer. 2008;8(1):11–23. doi: 10.1038/nrc2291.
- Nishino M, Klepeis VE, Yeap BY, et al. Histologic and cytomorphologic features of ALK-rearranged lung adenocarcinomas. Mod Pathol. 2012;25(11):1462–1472. doi: 10.1038/modpathol.2012.109.
Baylor University Medical Center Proceedings
The peer-reviewed journal of Baylor Scott & White Health
Volume 32, 2019 - Issue 2
Original Research
Histomorphologic features of lung adenocarcinomas exhibiting ALK gene rearrangement
Daniel S. GrosserDepartment of Pathology, Baylor University Medical Center, Dallas, TexasCorrespondence[email protected]
http://orcid.org/0000-0002-9834-616X
, MD http://orcid.org/0000-0002-9834-616X & , MD